Thanks for the abstract, Aslan. Post-secretional modifications are possible with GTC/Pharming’s technology, but they are not needed for ATryn, specifically. GTC’s Dr Meade has stated that the slightly different ratio of the AT isoforms between ATryn and plasma AT favors ATryn to a small degree by improving its binding affinity to heparin. This may help and it can’t hurt, so no attempt to change the ratio of the isoforms is undertaken.
Market Data 
Markets 
AI
